One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. The company was the target of an analyst price ...

Recursion Pharmaceuticals reported significant growth in sales and revenue for Q2 and the first half of 2025 but also experienced widening net losses. The release of their Boltz-2 model underscored a ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. RXRX stock looks like a deep-value growth bet at just $5 ...

A variation of a puzzle called the “pick-up sticks problem” asks the following question: If I have some number of sticks with random lengths between 0 and 1, what are the chances that no three of ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. 10 stocks we like better than Recursion Pharmaceuticals › ...

Recursion Pharmaceuticals RXRX is gearing up to announce its quarterly earnings on Tuesday, 2025-08-05. Here's a quick overview of what investors should know before the release. Analysts are ...

REC-3565, a MALT1 inhibitor developed via AI, is now in Phase 1 for blood cancers. REC-617 showed encouraging signs in a patient with recurrent ovarian cancer. Get the data-driven signals to profit ...

A team led by Regina Barzilay, a computer science professor at the Massachusetts Institute of Technology, has launched Boltz-2, an algorithm that unites protein folding and prediction of ...